Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
STERIS plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$219.54 |
52 Week High | US$254.00 |
52 Week Low | US$195.47 |
Beta | 0.85 |
11 Month Change | -1.74% |
3 Month Change | -2.35% |
1 Year Change | -2.42% |
33 Year Change | 4.73% |
5 Year Change | 43.70% |
Change since IPO | 10,544.36% |
Recent News & Updates
Recent updates
Is STERIS (NYSE:STE) Using Too Much Debt?
Jun 13Steris: Moving On, Losing Its Teeth
Apr 14STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 31% Above Its Share Price
Mar 29STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Mar 07Steris: Strong Healthcare Products Growth Coupled With Weak AST Business
Feb 17STERIS plc's (NYSE:STE) Business Is Trailing The Industry But Its Shares Aren't
Feb 15An Intrinsic Calculation For STERIS plc (NYSE:STE) Suggests It's 23% Undervalued
Dec 17Should You Investigate STERIS plc (NYSE:STE) At US$203?
Nov 24Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes
Nov 08We Think STERIS (NYSE:STE) Can Stay On Top Of Its Debt
Nov 06Are STERIS plc (NYSE:STE) Investors Paying Above The Intrinsic Value?
Sep 18Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage
Sep 01When Should You Buy STERIS plc (NYSE:STE)?
Aug 10Steris: Continuing To Grow The Product Lineup
Jun 20Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered
Feb 09Steris declares $0.47 dividend
Feb 01These 4 Measures Indicate That STERIS (NYSE:STE) Is Using Debt Reasonably Well
Feb 01Calculating The Intrinsic Value Of STERIS plc (NYSE:STE)
Dec 28Steris declares $0.47 dividend
Nov 02STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly
Nov 01Steris: Non-GAAP Valuations Supportive Of Substantial Upside
Sep 04STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.47
Aug 18STERIS' (NYSE:STE) Dividend Will Be Increased To $0.47
Aug 04Steris Non-GAAP EPS of $1.90 in-line, revenue of $1.2B misses by $20M
Aug 02Is STERIS (NYSE:STE) A Risky Investment?
Jul 19Steris: Deleveraging Key Undercurrent, Valuation A Concern
Jun 12STERIS (NYSE:STE) Seems To Use Debt Quite Sensibly
Apr 08Shareholder Returns
STE | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.7% | -0.8% | 0.04% |
1Y | -2.4% | -2.8% | 20.7% |
Return vs Industry: STE underperformed the US Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: STE underperformed the US Market which returned 22.5% over the past year.
Price Volatility
STE volatility | |
---|---|
STE Average Weekly Movement | 3.4% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: STE has not had significant price volatility in the past 3 months.
Volatility Over Time: STE's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 18,000 | Dan Carestio | www.steris.com |
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services.
STERIS plc Fundamentals Summary
STE fundamental statistics | |
---|---|
Market cap | US$21.40b |
Earnings (TTM) | US$551.44m |
Revenue (TTM) | US$5.14b |
39.4x
P/E Ratio4.2x
P/S RatioIs STE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STE income statement (TTM) | |
---|---|
Revenue | US$5.14b |
Cost of Revenue | US$2.90b |
Gross Profit | US$2.24b |
Other Expenses | US$1.69b |
Earnings | US$551.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.58 |
Gross Margin | 43.52% |
Net Profit Margin | 10.73% |
Debt/Equity Ratio | 50.8% |
How did STE perform over the long term?
See historical performance and comparison